Many tumors depend on growth factors, receptors and enzymes within biological pathways for proliferation, survival and differentiation. The growth factors interact with proteins in the cell membrane, including proteins called Type I receptor kinases, that transmit their growth signals into the cell through a cascade of enzymatic events. These receptors, including EGFR, ErbB-2, VEGF and PDGF, are found to be over-expressed, or over-activated, in numerous human tumors. Array’s programs focus on blocking multiple points along these pathways through targeted therapies offering a more specific approach than first generation, cytotoxic chemotherapies. By regulating discrete aspects of cellular functions that affect cancer cells to a greater extent than normal cells we can provide an improved side effect profile and increased efficacy. We believe cancer will eventually become a chronic disease, treated with a combination of targeted therapies. Array’s research focuses on creating orally active drugs that target novel mechanisms and are superior or complementary to other therapies.

According to estimates contained in the American Cancer Society, Surveillance Research Study for 2009, in the U.S. there will be an estimated 1.5 million new cases of cancer in 2009 and nearly 600 thousand cancer related deaths. The five-year relative survival rate for all cancers diagnosed between 1996 and 2004 was 66.0%. This represents a 16.0% improvement from 1975 to 1977. Earlier diagnosis and the use of new and/or improved treatments have driven this improvement. The following table shows estimated new cases diagnosed and estimated deaths in the U.S. for 2009 by major cancer type and types of interest to Array: